{
    "clinical_study": {
        "@rank": "153076", 
        "arm_group": [
            {
                "arm_group_label": "Tacrolimus", 
                "arm_group_type": "Active Comparator", 
                "description": "Patient recieved standard-dose of Tracolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician"
            }, 
            {
                "arm_group_label": "combination Tacrolimus and Sirolimus", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive combination of low-dose extended release Tacrolimus and low-dose Sirolimus"
            }
        ], 
        "brief_summary": {
            "textblock": "In this study we compare long term renal function in liver transplantation recipients\n      treated with standard dose extended-release tacrolimus alone and recipients treated with a\n      combination of low dose extended-release tacrolimus and low dose sirolimus. The hypothesis\n      is that the patients treated with the combination have better long term renal function than\n      the patients treated with standard dose tacrolimus alone."
        }, 
        "brief_title": "Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Liver Disease", 
        "condition_browse": {
            "mesh_term": "Liver Diseases"
        }, 
        "detailed_description": {
            "textblock": "To evaluate the effectiveness and safety of concentration controlled combination of once\n      daily dosed low-dose sirolimus (trough levels: 3-5 ng/ml) and extended-release tacrolimus\n      (trough levels:3-5 ng/ml), in order to provide superior renal function while maintaining\n      comparable rates of patient and graft survival, compared to concentration controlled once -\n      daily extended release tacrolimus (trough levels: 5-10 ng/ml) at 12, 24 and 36 months\n      post-transplant. Moreover, to compare the incidence of de novo malignancy, the quality of\n      life, fatigue and side effects between both treatment arms.\n\n      2.1 Primary objectives: To evaluate the effectiveness and safety of concentration controlled\n      combination of low-dose sirolimus (trough levels: 3-5 ng/ml) and extended-release tacrolimus\n      (trough levels: 3-5 ng/ml), in order to provide superior renal function while maintaining\n      comparable rates of patient and graft survival, compared to concentration controlled once -\n      daily extended release tacrolimus (trough levels:-10 ng/ml) control at 12, 24 and 36 months\n      post-transplant.\n\n      2.2. Secondary objectives:\n\n        -  To compare the incidence of de novo and recurrence of cancer between study arm and\n           control arm at 36 months.\n\n        -  To compare the incidence and severity of biopsy proven acute rejection between study\n           arm and control arm at 12, 24 and 36 months.\n\n        -  To evaluate renal function at 12, 24 and 36 months (calculated GFR).\n\n        -  To evaluate the development of new onset diabetes mellitus at 12, 24 and 36 months post\n           transplant\n\n        -  To evaluate the prevalence of CNI side effects at 12, 24 and 36 months\n\n        -  To evaluate quality of life (Eq5D) and fatigue severity score at 12, 24 and 36 months\n\n        -  To evaluate the percentage of patients on combination tacrolimus and sirolimus and\n           converted back to tacrolimus mono-therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Primary liver transplantation or retransplantation within 14 days after first\n             transplantation\n\n          -  Use of Advagraf  at least 2 weeks prior to randomization\n\n          -  Patent hepatic artery\n\n          -  Closed abdominal wound\n\n          -  Stable graft function\n\n          -  Positive informed consent at time of randomization\n\n          -  Age 18-70 years\n\n        Exclusion Criteria:\n\n          -  Treatment with investigational drugs within 3 months before start of therapy\n\n          -  Multi organ transplantation\n\n          -  cGFR < 30 ml/min\n\n          -  Proteinuria > 800 mg/24 h\n\n          -  Hyperlipidemia refractory to optimal medical management (Cholesterol > 9 mmol/l\n             and/or triglycerides > 8.5 mmol/l). Patients with controlled hyperlipidemia are\n             acceptable at the time of randomization.\n\n          -  Known hypersensitivity to sirolimus or its derivatives\n\n          -  Thrombocytes < 50 x 109 /L\n\n          -  Leukocytes < 2.5 x 109 /L\n\n          -  Haemoglobin < 6 mmol/L\n\n          -  Biopsy proven rejection 2 weeks  prior to randomization\n\n          -  HIV positivity\n\n          -  Signs of recurrent or de novo cancer\n\n          -  Patients with non-HCC malignancies within the past 5 years (excluding successfully\n             treated squamous cell carcinoma and basal cell carcinoma of the skin)\n\n          -  Evidence of significant local or systemic infection\n\n          -  Pregnancy or breast feeding\n\n          -  Women of child-bearing potential not willing to take oral contraception\n\n          -  Any other condition which in the opinion of the investigator would make the patient\n             unsuitable for enrollment, or could interfere with the patient participating in and\n             completing the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "196", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01958190", 
            "org_study_id": "LOL-III-1"
        }, 
        "intervention": [
            {
                "arm_group_label": "combination Tacrolimus and Sirolimus", 
                "description": "Arm 1 once daily combination therapy of normal dosed extended-release tacrolimus and prednisone for 3 months and monotherapy once daily extended-release tacrolimus thereafter up to 3 years after liver transplantation.\nArm 2 once daily combination therapy of low doses sirolimus and extended-release tacrolimus and prednisone for 3 months and combination therapy of low dose sirolimus and extended-release tacrolimus thereafter for up to 3 years after liver transplantation Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician Conversion to sirolimus (3-5 ng/ml)  and decrease Advagraf (3-5 ng/ml); 7.5 mg prednisone and lower or discontinue steroids after day 180 at the discretion of the treating physician", 
                "intervention_name": "Tacrolimus and Sirolimus", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Advagraf [Astellas Pharma bv)", 
                    "Rapamune"
                ]
            }, 
            {
                "arm_group_label": "Tacrolimus", 
                "description": "Patient recieved standard-dose of Tracolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician", 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug", 
                "other_name": "Advagraf"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Liver transplantation long term renal function", 
            "tacrolimus sirolimus"
        ], 
        "lastchanged_date": "October 8, 2013", 
        "location": {
            "contact": {
                "last_name": "Herold J Metselaar, MD PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Rotterdam", 
                    "country": "Netherlands", 
                    "zip": "3015CE"
                }, 
                "name": "Erasmus Medical Center"
            }, 
            "investigator": {
                "last_name": "Herold J Metselaar, MD PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter Randomized in Primary Livertransplantation Comparing Longterm Renal Function in Recipients Treated With Tacrolimus Alone and Recipients Treated With a Combination Tacrolimus and Sirolimus", 
        "overall_contact": {
            "email": "h.j.metselaar@erasmusmc.nl", 
            "last_name": "Herold J Metselaar, MD PhD"
        }, 
        "overall_official": {
            "affiliation": "Erasmus Medical Center Rotterdam", 
            "last_name": "Herold J Metselaar, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Renal function", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01958190"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Malignancies", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "de novo Diabetes Mellitus", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Foundation for Liver Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Foundation for Liver Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}